Connected profiles2
Exact peptide identities attached to retained registry observations carrying this condition label.
Coverage-gated living condition brief
Metabolism and Nutrition Disorder peptide evidence brief
A cited Metabolism and Nutrition Disorder peptide evidence brief across 3 exact-label ClinicalTrials.gov records, 2 connected profiles, and 3 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
3 selected records.
Connected peptides
2 profiles.
Registry update years
2017–2023 in selected records.
Direct collection answer · published August 17, 2026
What peptide evidence does PeptideScanner carry for Metabolism and Nutrition Disorder?
PeptideScanner’s selected collection contains 3 retained ClinicalTrials.gov records carrying the exact condition label “Metabolism and Nutrition Disorder,” connected to 2 peptide profiles across 3 registry-update years.
That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Metabolism and Nutrition Disorder, and it is not a safety or efficacy assessment.
Indication intelligence
Selected evidence landscape
Trial phases2
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 3 (1)Phase 1 (1)
Registry statuses1
Overall statuses at each retained observation, not necessarily current today.
Completed (3)
Across the connected peptide profiles, PeptideScanner also carries 148 selected PubMed records and 18 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Metabolism and Nutrition Disorder unless their own cited source says so.
Related profile context
Literature connected through these peptide profiles
This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Metabolism and Nutrition Disorder.
Semaglutide · source record 2026-08-15
Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.
PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Liraglutide · source record 2026-08-14
Treatment of obesity with liraglutide in bipolar disorder: a case report.
PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Semaglutide · source record 2026-08-13
Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.
PubMed lists PMID 41938304 in AACE endocrinology and diabetes as Journal Article, Review, with publication-date metadata of 2026-01-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Liraglutide · source record 2026-08-13
Application of the OBIMAP (One-Bead Interchain Multipeptide Assembly Platform) to Long Peptide Synthesis: Liraglutide as a Case Study.
PubMed lists PMID 41970854 in ACS omega as Journal Article, with publication-date metadata of 2026-03-25 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Semaglutide · source record 2026-08-13
Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet.
PubMed lists PMID 42076092 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Liraglutide · source record 2026-07-15
Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions.
PubMed lists PMID 41966799 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT02079870
PeptideScanner retained ClinicalTrials.gov record NCT02079870 at 2026-07-30T21:22:00.245Z. Its registry update date was 2017-12-02, and PeptideScanner's reviewed identity mapping was semaglutide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- December 2, 2017
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT02967757
PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- January 20, 2023
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT03548987
PeptideScanner retained ClinicalTrials.gov record NCT03548987 at 2026-07-30T19:44:52.954Z. Its registry update date was 2022-01-19, and PeptideScanner's reviewed identity mapping was semaglutide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- January 19, 2022
- Evidence lane
- Clinical trials
Exact-record source chronology
Metabolism and Nutrition Disorder registry timeline
Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.
2023
1 recordLiraglutide · 2023-01-20
ClinicalTrials.gov record NCT02967757
Completed at the retained observation.
Open cited registry record →2022
1 recordSemaglutide · 2022-01-19
ClinicalTrials.gov record NCT03548987
Completed at the retained observation.
Open cited registry record →2017
1 recordSemaglutide · 2017-12-02
ClinicalTrials.gov record NCT02079870
Completed at the retained observation.
Open cited registry record →- Condition matching is limited to exact labels on retained ClinicalTrials.gov v3 observations; PeptideScanner does not merge related diagnoses or synonyms.
- Coverage is selective and historical, not a complete or continuously current account of the registry or PubMed.
- The brief does not synthesize study outcomes, compare interventions, or make safety, efficacy, diagnosis, or treatment claims.